Stoke Therapeutics (NASDAQ:STOK) Shares Up 6.9% – Time to Buy?

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) were up 6.9% during mid-day trading on Wednesday . The company traded as high as $10.00 and last traded at $10.50. Approximately 13,795 shares changed hands during trading, a decline of 98% from the average daily volume of 822,257 shares. The stock had previously closed at $9.82.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on STOK. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Chardan Capital started coverage on Stoke Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $24.00 price target on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Leerink Partners started coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Price Performance

The firm’s fifty day moving average is $11.09 and its 200 day moving average is $12.73. The firm has a market capitalization of $549.72 million, a price-to-earnings ratio of -4.99 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Insider Activity

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $78,852.60. Following the completion of the sale, the chief executive officer now directly owns 68,671 shares in the company, valued at $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the transaction, the insider now directly owns 47,332 shares of the company’s stock, valued at $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock worth $809,421 in the last three months. 11.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in Stoke Therapeutics during the fourth quarter valued at about $124,000. Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $160,000. The Manufacturers Life Insurance Company raised its stake in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares in the last quarter. Mesirow Financial Investment Management Inc. acquired a new position in shares of Stoke Therapeutics in the third quarter valued at $192,000. Finally, American Century Companies Inc. lifted its position in Stoke Therapeutics by 99.4% in the second quarter. American Century Companies Inc. now owns 59,149 shares of the company’s stock worth $799,000 after purchasing an additional 29,489 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.